Literature DB >> 24501180

The Subjective Quality of Life in Young People With Tourette Syndrome in China.

Shiguo Liu1, Lanlan Zheng1, Xueping Zheng1, Xinhua Zhang1, Mingji Yi1, Xu Ma2,3.   

Abstract

OBJECTIVE: To explore the subjective quality of life (QoL) in children with Tourette Syndrome (TS) in China to provide a basis for more effective interference.
METHOD: A total of 107 patients and 107 controls were enrolled. Subjective QoL was investigated by Inventory of Subjective Life Quality, Family Environment Scale of Chinese Version, and the Yale Global Tic Severity Scale, and a case-control study was performed.
RESULTS: The total score of subjective QoL and family life, school life, peer relationship, cognitive component, environment, self-awareness, cognitive component and depression experience in the TS were lower than control. Patients with co-morbid exhibited significantly lower scores within the subjective QoL family life, peer relationship, school life, self-awareness, and cognitive affective domains.
CONCLUSION: The subjective QoL is impaired and it is important to control clinical symptoms and improve family environment for the improvement of the subjective QoL in TS.

Entities:  

Keywords:  China; Tourette syndrome; child; quality of life

Mesh:

Year:  2016        PMID: 24501180     DOI: 10.1177/1087054713518822

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  7 in total

1.  Gastrodin Attenuates Tourette Syndrome by Regulating EAATs and NMDA Receptors in the Striatum of Rats.

Authors:  Xueran Sun; Xin Zhang; Keyu Jiang; Min Wu
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-12       Impact factor: 2.570

Review 2.  European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment.

Authors:  Kirsten R Müller-Vahl; Danielle C Cath; Natalia Szejko; Sally Robinson; Andreas Hartmann; Christos Ganos; Nanette M Debes; Liselotte Skov; Martina Haas; Renata Rizzo; Jeremy Stern; Alexander Münchau; Virginie Czernecki; Andrea Dietrich; Tara L Murphy; Davide Martino; Zsanett Tarnok; Tammy Hedderly
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-10-18       Impact factor: 4.785

3.  ASH1L may contribute to the risk of Tourette syndrome: Combination of family-based analysis and case-control study.

Authors:  Wenmiao Liu; Lulu Xu; Cheng Zhang; Lu Shen; Jicheng Dong; Han Zhang; Shiguo Liu; Fengyuan Che; Xueping Zheng
Journal:  Brain Behav       Date:  2022-03-20       Impact factor: 3.405

4.  Mutations in ASH1L confer susceptibility to Tourette syndrome.

Authors:  Shiguo Liu; Miaomiao Tian; Fan He; Jiani Li; Hong Xie; Wenmiao Liu; Yeting Zhang; Ru Zhang; Mingji Yi; Fengyuan Che; Xu Ma; Yi Zheng; Hao Deng; Guiju Wang; Lang Chen; Xue Sun; Yinglei Xu; Jingli Wang; Yucui Zang; Mengmeng Han; Xiuhai Wang; Hongzai Guan; Yinlin Ge; Chunmei Wu; Haiyan Wang; Hui Liang; Hui Li; Ni Ran; Zhaochuan Yang; Huanhuan Huang; Yanzhao Wei; Xueping Zheng; Xiangrong Sun; Xueying Feng; Lanlan Zheng; Tao Zhu; Wenhan Luo; Qinan Chen; Yuze Yan; Zuzhou Huang; Zhongcui Jing; Yixia Guo; Xuzhan Zhang; Christian P Schaaf; Jinchuan Xing; Chuanyue Wang; Fuli Yu; Ji-Song Guan
Journal:  Mol Psychiatry       Date:  2019-10-31       Impact factor: 15.992

5.  Comorbidities, Social Impact, and Quality of Life in Tourette Syndrome.

Authors:  Valsamma Eapen; Andrea E Cavanna; Mary M Robertson
Journal:  Front Psychiatry       Date:  2016-06-06       Impact factor: 4.157

Review 6.  The effects of Gilles de la Tourette syndrome and other chronic tic disorders on quality of life across the lifespan: a systematic review.

Authors:  Joel Evans; Stefano Seri; Andrea E Cavanna
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-02-15       Impact factor: 4.785

7.  The Effect of a New Therapy for Children with Tics Targeting Underlying Cognitive, Behavioral, and Physiological Processes.

Authors:  Julie B Leclerc; Kieron P O'Connor; Gabrielle J-Nolin; Philippe Valois; Marc E Lavoie
Journal:  Front Psychiatry       Date:  2016-08-11       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.